IP Library Granted Patent US 7,141,392
Granted Patent B2
US 7,141,392 · App. 10/753,181 · Granted Nov 28, 2006

Latent fusion protein

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,141,392
App. No.
10/753,181
Granted
Nov 28, 2006
Kind
B2
Abstract

The present invention provides a method for providing latency to a pharmaceutically active agent. The method has application in overcoming the toxic effect of systemic administration of potent biological agents. The method comprises associating a fusion protein comprising a latency associated peptide and a proteolytic cleavage site with a pharmaceutically active agent. The fusion protein also has application in providing site specific activation to a latent pharmaceutically active agent.

Claims (9)

1. An isolated nucleic acid construct encoding a fusion protein wherein said nucleic acid comprises: a first nucleic acid sequence encoding a biologically active protein; a second nucleic acid sequence encoding a heterologous latency associated peptide (LAP) comprising the precursor domain of TGFβ; and a third nucleic acid sequence encoding a proteolytic cleavage site between the first and second nucleic acid sequences.

2. The nucleic acid construct of claim 1 , wherein said biologically active protein comprises a growth factor; a differentiation factor, a cytokine, a chemokine, a trophic factor, a cytokine inhibitor, a cytokine receptor, a free-radical scavenging enzyme, a tissue inhibitor of a metalloproteinase, or an inhibitor of a serine protease.

3. The nucleic acid construct of claim 1 , wherein said first nucleic acid sequence encodes an interferon.

4. The nucleic acid construct of claim 1 , wherein said first nucleic acid sequence encodes an interleukin.

5. The nucleic acid construct of claim 1 , wherein said latency associated peptide comprises the precursor peptide of TGFβ-1,2,3,4 or 5.

6. The nucleic acid construct of claim 1 or claim 2 , wherein said proteolytic cleavage site is a matrix metalloproteinase (MMP) cleavage site.

7. A vector comprising the nucleic acid construct of claim 1 .

8. An isolated host cell comprising the vector of claim 7 .

9. A process for preparing a recombinant fusion protein comprising a biologically active protein, a LAP, and a proteolytic cleavage site, comprising culturing the host cell of claim 8 under conditions such that said fusion protein is expressed and recovering said fusion protein.

Assignments (3)
CHANGE OF ADDRESS Recorded Sep 19, 2016
From: STEALTHYX THERAPEUTICS LIMITED
To: STEALTHYX THERAPEUTICS LIMITED
Reel/Frame 040073/0246 →
CHANGE OF NAME Recorded Jun 3, 2015
From: QUEEN MARY & WESTFIELD COLLEGE
To: QUEEN MARY UNIVERSITY OF LONDON
Reel/Frame 035776/0500 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 3, 2015
From: QUEEN MARY UNIVERSITY OF LONDON
To: STEALTHYX THERAPEUTICS LIMITED
Reel/Frame 035776/0582 →